Profile: AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

4,385.50GBp
8:05am EDT
Price Change (% chg)

100.50p (+2.35%)
Prev Close
4,285.00p
Open
4,304.00p
Day's High
4,390.00p
Day's Low
4,293.50p
Volume
1,364,702
Avg. Vol
2,320,535
52-wk High
4,946.41p
52-wk Low
3,085.21p

Search Stocks
AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. AstraZeneca discovers, develops and commercializes prescription medicines for six areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation. It has a range of medicines that includes treatments for illnesses, such as its antibiotic, Merrem/Meronem and Losec/Prilosec for acid related diseases. AstraZeneca’s products include Crestor, Atacand,Seloken/Toprol-XL, Plendil, Onglyza, Zestril, Symbicort and Zoladex. The Company owns and operates a range of research and development (R&D), production and marketing facilities worldwide. AstraZeneca operates in over 100 countries, including China, Mexico, Brazil and Russia. In January 2014, Probiodrug AG transferred its experimental cyclin-dependent kinase 9 (CDK9) inhibitor program to AstraZeneca. In February 2014, Bristol-Myers Squibb Co completed the sale of its global diabetes business to AstraZeneca.

Company Address

AstraZeneca PLC

2 Kingdom Street, Paddington
LONDON   ENG   W2 6BD
P: +4420.76048000
F: +4420.76048151

Search Stocks